Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
Neuralstem has asked the Food and Drug Administration to approve an early-stage safety study on a potential spinal cord injury treatment, the company said Wednesday.
The treatment was developed using adult stem-cell technology, specifically with stem cells taken from the spinal cord.
Shares of Neuralstem Inc. rose 20 cents, or 11.1 percent, to $2 in afternoon trading. The stock has traded between $1.04 and $3.49 over the last 52 weeks.